Patents by Inventor Fiona MACK

Fiona MACK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF SOLID TUMORS
    Publication number: 20220378722
    Abstract: The instant invention relates to therapeutic combinations of LSD1 inhibitors and one or more other active pharmaceutical ingredient(s) or pharmaceutically acceptable salts thereof. The combinations are particularly useful for treating neoplastic diseases, such as cancer, particularly small cell lung cancer (SCLC).
    Type: Application
    Filed: May 4, 2022
    Publication date: December 1, 2022
    Inventors: Mark D. DEMARIO, Tamara MAES, William E. PIERCEALL, Fiona MACK, Serena LUNARDI
  • PHARMACODYNAMIC BIOMARKERS FOR PERSONALIZED CANCER CARE USING EPIGENETIC MODIFYING AGENTS
    Publication number: 20190256929
    Abstract: The invention provides methods of monitoring differential gene expression of pharmacodynamic (PD) biomarkers in patients treated with Lysine Demethylase 1 (LSD 1) inhibitors and methods of determining the sensitivity of a cell to an LSD 1 inhibitor by measuring PD biomarkers.
    Type: Application
    Filed: November 2, 2017
    Publication date: August 22, 2019
    Inventors: Fabian BIRZELE, Wei-Yi CHENG, Mark D. DEMARIO, Fiona MACK, Francesca MILLETTI, William E. PIERCEALL
  • GENE EXPRESSION BIOMARKERS FOR PERSONALIZED CANCER CARE TO EPIGENETIC MODIFYING AGENTS
    Publication number: 20190153538
    Abstract: The present application discloses a method to predict responsiveness of a patient, with cancer, to treatment with LSD1 inhibitors, said method comprising measuring mRNA expression levels of one or more genes selected from the list of ASCL1, DDC, CEACAM6, LRRIQ4, NR0B2, GRP, CEACAM5, SOX21, OR51E2, SEC11C, BAALC, CCDC40, RAB3B, RGS17, ABCE1, ETS2, CCDC154, SPAG6, PON1, TMEM176A, C1orf127, IGF2BP2, IGFBP5, FAM84A, FOXA2, HOXA10, NCAM1, NCAM2, NEUROD1, KRT8, ENO2, AVP, OXT, SYP, CHGA, CHGB, BCL2 and MYC.
    Type: Application
    Filed: October 8, 2016
    Publication date: May 23, 2019
    Inventors: Wei-Yi CHENG, Mark D. DEMARIO, Fiona MACK, Francesca MILLETTI, William E. PIERCEALL
  • Combinations of LSD1 inhibitors for use in the treatment of solid tumors
    Patent number: 10265279
    Abstract: The instant invention relates to therapeutic combinations of LSD1 inhibitors and one or more other active pharmaceutical ingredient(s) or pharmaceutically acceptable salts thereof. The combinations are particularly useful for treating neoplastic diseases, such as cancer, particularly small cell lung cancer (SCLC).
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: April 23, 2019
    Assignee: Oryzon Genomics, S.A.
    Inventors: Mark D. Demario, Tamara Maes, William E. Pierceall, Fiona Mack, Serena Lunardi
  • COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF SOLID TUMORS
    Publication number: 20170281567
    Abstract: The instant invention relates to therapeutic combinations of LSD1 inhibitors and one or more other active pharmaceutical ingredient(s) or pharmaceutically acceptable salts thereof. The combinations are particularly useful for treating neoplastic diseases, such as cancer, particularly small cell lung cancer (SCLC).
    Type: Application
    Filed: March 14, 2017
    Publication date: October 5, 2017
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Mark D. DEMARIO, Tamara MAES, William E. PIERCEALL, Fiona MACK, Serena LUNARDI